Tasidotin Hydrochloride

N/A

Report date: 2022/03/17 09:47:26
NME

Base Information

Drug NameTasidotin Hydrochloride
Drug Alias Name泰斯多汀盐酸盐tasidotinumSynthadotin他西多丁盐酸盐tasidotine +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase inhibitorsTubulin inhibitors
TargetsDNA topoisomeraseTubulin
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesGenzyme Corp
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG